202 related articles for article (PubMed ID: 29595102)
1. Pasireotide - Mechanism of Action and Clinical Applications.
Sawicka-Gutaj N; Owecki M; Ruchala M
Curr Drug Metab; 2018; 19(10):876-882. PubMed ID: 29595102
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide (SOM230): development, mechanism of action and potential applications.
Schmid HA
Mol Cell Endocrinol; 2008 May; 286(1-2):69-74. PubMed ID: 17977644
[TBL] [Abstract][Full Text] [Related]
5. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
Silverstein JM
Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide in Acromegaly: A Review.
McKeage K
Drugs; 2015 Jun; 75(9):1039-48. PubMed ID: 26017304
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
9. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide: a review of its use in Cushing's disease.
McKeage K
Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide for the treatment of Cushing's disease.
Arnaldi G; Boscaro M
Expert Opin Investig Drugs; 2010 Jul; 19(7):889-98. PubMed ID: 20533892
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing's disease receiving pasireotide treatment:
Feldt-Rasmussen U; Bolanowski M; Zhang SL; Yu Y; Witek P; Kalra P; Kietsiriroje N; Piacentini A; Pedroncelli AM; Samson SL
Front Endocrinol (Lausanne); 2024; 15():1250822. PubMed ID: 38577574
[TBL] [Abstract][Full Text] [Related]
14. Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D; Fleseriu M
Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
[TBL] [Abstract][Full Text] [Related]
18. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
Colao A; De Block C; Gaztambide MS; Kumar S; Seufert J; Casanueva FF
Pituitary; 2014 Apr; 17(2):180-6. PubMed ID: 23564338
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide.
Prescrire Int; 2013 Nov; 22(143):257-9. PubMed ID: 24427831
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM; Hu K; Hughes G; Bouillaud E; Giannone V; Resendiz KH
Cancer Chemother Pharmacol; 2013 Aug; 72(2):387-95. PubMed ID: 23765178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
